Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:5409
Name lung small cell carcinoma
Definition A lung carcinoma that has_material_basis_in primitive-appearing cells that are smaller than normal cells and is located_in the lung.
Source DiseaseOntology.org
Alt Ids DOID:0050875
Path disease disease of cellular proliferation cancer organ system cancer respiratory system cancer lung cancer lung carcinoma lung small cell carcinoma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
TP53 inact mut APR-246 lung small cell carcinoma sensitive detail...
RET wild-type Vandetanib lung small cell carcinoma sensitive detail...
RET M918T Ponatinib lung small cell carcinoma sensitive detail...
RET wild-type Ponatinib lung small cell carcinoma sensitive detail...
RET M918T Vandetanib lung small cell carcinoma sensitive detail...
FGFR1 amp Debio 1347 lung small cell carcinoma sensitive detail...
TP53 Y163C APR-246 + Cisplatin lung small cell carcinoma sensitive detail...
RB1 loss Trilaciclib lung small cell carcinoma resistant detail...
RB1 loss Topotecan + Trilaciclib lung small cell carcinoma sensitive detail...
FGFR1 amp AZD4547 lung small cell carcinoma sensitive detail...
PIK3CA act mut Navitoclax + Pictilisib lung small cell carcinoma predicted - sensitive detail...
TP53 S241F APR-246 lung small cell carcinoma sensitive detail...
TP53 R273L APR-246 lung small cell carcinoma sensitive detail...
FGFR1 amp RO4987655 lung small cell carcinoma no benefit detail...
FGFR1 amp RO5126766 lung small cell carcinoma no benefit detail...
FGFR1 amp Selumetinib lung small cell carcinoma no benefit detail...
FGFR1 rearrange AZD4547 lung small cell carcinoma sensitive detail...
FGFR1 amp E7090 lung small cell carcinoma sensitive detail...
ALK rearrange RB1 C706F TP53 loss Lorlatinib lung small cell carcinoma predicted - resistant detail...
FGFR1 amp AZD4547 + Buparlisib lung small cell carcinoma sensitive detail...
FGFR1 amp GSK3052230 lung small cell carcinoma sensitive detail...
FGFR1 amp Cisplatin + Etoposide + GSK3052230 lung small cell carcinoma sensitive detail...
CHEK1 over exp PF-00477736 lung small cell carcinoma sensitive detail...
CHEK1 over exp Berzosertib lung small cell carcinoma sensitive detail...
ATM D2725G Temozolomide + Veliparib lung small cell carcinoma predicted - sensitive detail...
ATM S333F Temozolomide + Veliparib lung small cell carcinoma predicted - sensitive detail...
ATM V410A Temozolomide + Veliparib lung small cell carcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00720785 Phase I Bortezomib Natural Killer Cells and Bortezomib to Treat Cancer Completed USA 0
NCT00926640 Phase I Belinostat + Cisplatin + Etoposide A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers Completed USA 0
NCT01286987 Phase I Talazoparib Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors Completed USA 1
NCT01306045 Phase II Erlotinib Lapatinib MK2206 Sunitinib Selumetinib Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies Active, not recruiting USA 0
NCT01450761 Phase III Cisplatin Ipilimumab Carboplatin Etoposide Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone Completed USA | CAN 32
NCT01579929 Phase I Cisplatin + Etoposide + Sonidegib Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Completed USA 0
NCT01587703 Phase I Molibresib A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers Completed USA 6
NCT01638546 Phase II Temozolomide Veliparib Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer Completed USA 0
NCT01642251 Phase Ib/II Cisplatin + Etoposide Veliparib Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer Completed USA 0
NCT01722292 Phase Ib/II Taladegib Carboplatin + Etoposide A Study of LY2940680 in Small Cell Lung Cancer Terminated USA 1
NCT01737502 Phase Ib/II Auranofin + Sirolimus Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer Recruiting USA 0
NCT01831089 Phase I Bevacizumab + Lurbinectedin + Paclitaxel Lurbinectedin + Paclitaxel Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors Completed USA 2
NCT01859741 Phase Ib/II Cisplatin Etoposide Carboplatin Tarextumab A Phase 1b/2 Study of OMP-59R5 in Combination With Etoposide and Platinum Therapy in Subjects With Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE) Terminated USA 0
NCT01892046 Phase I Carboplatin SNX-5422 Paclitaxel Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors Completed USA 0
NCT01928394 Phase Ib/II Ipilimumab + Nivolumab Cobimetinib + Ipilimumab + Nivolumab Nivolumab A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors Active, not recruiting USA | CAN 6
NCT02034123 Phase I GSK2879552 Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma Terminated USA 2
NCT02038647 Phase II Paclitaxel Alisertib Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC) Completed USA | CAN 8
NCT02100007 Phase Ib/II ME-344 + Topotecan ME-344 Given in Combination With Hycamtin in Patients With Solid Tumors Terminated USA 1
NCT02152059 Phase II Nintedanib A Study to Evaluate the Good and Bad Effects of BIBF1120 in Small Cell Lung Cancer Patients Who Have Previously Benefited From First-line Platinum-based Chemotherapy Withdrawn CAN 0
NCT02157792 Phase I Berzosertib + Irinotecan Berzosertib + Cisplatin + Gemcitabine Berzosertib + Cisplatin + Etoposide Berzosertib + Cisplatin Berzosertib + Carboplatin + Cisplatin Berzosertib + Gemcitabine M6620 First in Human Study Completed USA 1
NCT02161419 Phase II Roniciclib RONICICLIB / Placebo in Combination With Chemotherapy in Small Cell Lung Cancer Terminated USA 8
NCT02200757 Phase II Aldoxorubicin Topotecan Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer Unknown status USA 2
NCT02247349 Phase Ib/II BMS-986012 BMS-986012 + Nivolumab BMS-986012 in Relapsed/Refractory SCLC Active, not recruiting USA | CAN 5
NCT02250885 Phase II Selinexor KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors Completed USA 0
NCT02261805 Phase Ib/II Aldoxorubicin + Ganetespib A Phase I/II Study of Ganetespib in Combination With Doxorubicin Terminated USA 0
NCT02289690 Phase I Carboplatin + Etoposide + Veliparib Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer Completed USA | CAN 10
NCT02331251 Phase Ib/II Vinorelbine Pembrolizumab Irinotecan Doxorubicin Gemcitabine Docetaxel Nab-paclitaxel Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) Terminated USA 0
NCT02351505 Phase II Selinexor Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer Terminated USA 0
NCT02359019 Phase II Pembrolizumab Pembrolizumab in Treating Patients With Extensive Stage Small Cell Lung Cancer After Completion of Combination Chemotherapy Active, not recruiting USA 0
NCT02402920 Phase I Carboplatin + Etoposide + Pembrolizumab Cisplatin Phase I Trial of MK-3475 and Concurrent Chemo/Radiation for the Elimination of Small Cell Lung Cancer Recruiting USA 0
NCT02419417 Phase Ib/II BMS986158 Paclitaxel Study of BMS-986158 in Subjects With Select Advanced Solid Tumors Active, not recruiting USA | CAN 3
NCT02446704 Phase Ib/II Olaparib Temozolomide Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy Active, not recruiting USA 0
NCT02454972 Phase II Lurbinectedin Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors Completed USA 8
NCT02472977 Phase Ib/II Nivolumab Ulocuplumab Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors Terminated USA 1
NCT02481830 Phase III Amrubicin Nivolumab Topotecan Efficacy Study of Nivolumab or Chemotherapy in Subjects With Relapsed Small-cell Lung Cancer Active, not recruiting USA 24
NCT02487095 Phase Ib/II Berzosertib Topotecan Trial of Topotecan With VX-970, an ATR Kinase Inhibitor, in Small Cell Lung Cancer Active, not recruiting USA 0
NCT02489903 Phase II Etoposide RRx-001 Carboplatin Cisplatin Nab-paclitaxel RRx-001 in Small, Non-small Cell Lung Cancer, and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens Active, not recruiting USA 0
NCT02498613 Phase II Cediranib + Olaparib A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors Recruiting USA | CAN 0
NCT02499770 Phase Ib/II Carboplatin + Etoposide Trilaciclib G1T28 (CDK 4/6 Inhibitor) in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC) Completed USA 6
NCT02514447 Phase Ib/II Trilaciclib Topotecan Study of G1T28 in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy Active, not recruiting USA 7
NCT02516553 Phase I BI 894999 BI 894999 First in Human Dose Finding Study in Advanced Malignancies Active, not recruiting USA 5
NCT02537418 Phase I Cisplatin + Etoposide Durvalumab Tremelimumab Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Receiving Standard Chemotherapy Regimens Active, not recruiting CAN 0
NCT02538666 Phase III Ipilimumab Nivolumab A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination With Ipilimumab, or Placebo as Maintenance Therapy in Subjects With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based First Line Chemotherapy (CheckMate 451) Active, not recruiting USA | CAN 30
NCT02561234 Phase I Pegzilarginase A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors Completed USA 0
NCT02579226 Phase I Irinotecan AZD2811 A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors Completed USA 0
NCT02611024 Phase Ib/II Irinotecan + Lurbinectedin Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors Recruiting USA 1
NCT02628067 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Recruiting USA | CAN 19
NCT02631733 Phase I Irinotecan + Veliparib Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Active, not recruiting USA 0
NCT02646748 Phase I Itacitinib + Pembrolizumab Parsaclisib + Pembrolizumab Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors Active, not recruiting USA 0
NCT02649673 Phase Ib/II LCL161 + Topotecan LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies Terminated USA 0
NCT02658214 Phase I Cisplatin + Durvalumab + Fluorouracil + Tremelimumab Durvalumab + Gemcitabine + Nab-paclitaxel + Tremelimumab Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin + Tremelimumab Carboplatin + Durvalumab + Nab-paclitaxel + Tremelimumab Carboplatin + Durvalumab + Etoposide + Tremelimumab Carboplatin + Durvalumab + Paclitaxel + Tremelimumab Carboplatin + Durvalumab + Gemcitabine + Tremelimumab Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors Completed 2
NCT02660034 Phase I Pamiparib + Tislelizumab The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors Completed USA 5
NCT02671955 Phase I JNJ-61610588 A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer Terminated USA 0
NCT02674568 Phase II Rovalpituzumab Tesirine Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY) Completed 0
NCT02701400 Phase II Tavolimab + Tremelimumab Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer Completed USA 0
NCT02734004 Phase Ib/II Durvalumab + Olaparib Bevacizumab + Durvalumab + Olaparib A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (MEDIOLA) Completed USA 6
NCT02735980 Phase II Prexasertib A Study of LY2606368 in Participants With Extensive Stage Disease Small Cell Lung Cancer Completed USA 9
NCT02748889 Phase Ib/II Carboplatin + Etoposide Atezolizumab + Carboplatin + Etoposide Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer Terminated USA 0
NCT02763579 Phase III Atezolizumab + Carboplatin + Etoposide Carboplatin + Etoposide A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer (IMpower133) Active, not recruiting USA 20
NCT02815592 Phase Ib/II Etoposide BMS-986012 + Cisplatin + Etoposide BMS-986012 + Carboplatin + Etoposide Trial of BMS-986012 in Combination With Platinum and Etoposide Active, not recruiting 1
NCT02819999 Phase I Cisplatin + Etoposide + Rovalpituzumab Tesirine Rovalpituzumab Tesirine A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Delta-Like Protein 3-Expressing Extensive Stage Small Cell Lung Cancer Terminated USA 0
NCT02874664 Phase I Rovalpituzumab Tesirine A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer Completed USA | CAN 0
NCT02875223 Phase I CC-90011 A Safety and Efficacy Study of CC-90011 in Subjects With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas Recruiting 5
NCT02899728 Phase II Carboplatin + Cisplatin + Etoposide Cediranib + Olaparib Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer Terminated USA 0
NCT02922764 Phase I RGX-104 Ipilimumab + RGX-104 Nivolumab + RGX-104 Carboplatin + Pembrolizumab + Pemetrexed Disodium + RGX-104 A Study of RGX-104 With or Without Nivolumab in Patients With Advanced Solid Malignancies and Lymphoma Recruiting USA 0
NCT02934503 Phase II Carboplatin + Cisplatin + Etoposide + Pembrolizumab Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC) Terminated USA 0
NCT02936323 Phase Ib/II PEN-221 PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers Completed USA 1
NCT02963090 Phase II Pembrolizumab + Topotecan Pembrolizumab Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer Unknown status USA 0
NCT03026166 Phase I Ipilimumab + Nivolumab + Rovalpituzumab Tesirine Nivolumab + Rovalpituzumab Tesirine A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer Terminated USA 4
NCT03033511 Phase III Dexamethasone + Rovalpituzumab Tesirine A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU) (MERU) Terminated USA | CAN 39
NCT03041311 Phase II Atezolizumab + Carboplatin + Etoposide + Trilaciclib Atezolizumab + Carboplatin + Etoposide Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Extensive Stage Small Cell Lung Cancer (SCLC) Active, not recruiting USA 6
NCT03043599 Phase Ib/II Ipilimumab + Nivolumab Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer Active, not recruiting USA 0
NCT03043872 Phase III Carboplatin + Cisplatin + Durvalumab + Etoposide + Tremelimumab Carboplatin + Cisplatin + Durvalumab + Etoposide Carboplatin + Cisplatin + Etoposide Durvalumab+/- Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (Caspian) Active, not recruiting USA 22
NCT03061812 Phase III Rovalpituzumab Tesirine Topotecan Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE) (TAHOE) Completed USA | CAN 31
NCT03066778 Phase III Cisplatin + Etoposide Cisplatin + Etoposide + Pembrolizumab Carboplatin + Etoposide + Pembrolizumab Carboplatin + Etoposide A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604) Completed USA | CAN 17
NCT03076372 Phase I MM-310 A Study Evaluating MM-310 in Patients With Solid Tumors Unknown status USA 0
NCT03080311 Phase I APG-1252 A Study of APG-1252 in Patients With SCLC or Other Solid Tumors Completed USA 0
NCT03083691 Phase II Ipilimumab + Nivolumab BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer Enrolling by invitation 1
NCT03085849 Phase I Durvalumab + Guadecitabine + Tremelimumab SGI-110 Plus Durvalumab/Tremelimumab in SCLC Completed USA 0
NCT03092934 Phase Ib/II LY3295668 A Study of AK-01 (LY3295668) in Solid Tumors Completed CAN 0
NCT03116971 Phase Ib/II Cisplatin + Etoposide + MSC2490484A MSC2490484A Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED) Terminated USA | CAN 11
NCT03150810 Phase Ib/II Pamiparib + Temozolomide Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors Recruiting USA 3
NCT03179436 Phase Ib/II MK-1308 + Pembrolizumab MK-1308 Safety, Pharmacokinetics (PK), and Efficacy of MK-1308 in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001) Recruiting USA | CAN 14
NCT03212404 Phase I Cosibelimab Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers Recruiting 9
NCT03221400 Phase Ib/II STA-8666 PEN-866 in Patients With Advanced Solid Malignancies Recruiting USA 0
NCT03227016 Phase I Topotecan + Veliparib Study in Patients With SCLC of Veliparib in Combination With Topotecan Recruiting 1
NCT03313778 Phase I mRNA-4157 + Pembrolizumab mRNA-4157 Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors (KEYNOTE-603) Recruiting USA 0
NCT03319940 Phase I AMG 757 Study Evaluating Safety, Tolerability and PK of AMG 757 in Adults With Small Cell Lung Cancer Recruiting USA 9
NCT03325816 Phase Ib/II Nivolumab Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer Completed USA 0
NCT03334487 Phase III Dexamethasone + Rovalpituzumab Tesirine Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer Withdrawn USA | CAN 5
NCT03361228 Phase Ib/II Epacadostat + INCB001158 Epacadostat + INCB001158 + Pembrolizumab A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors Terminated USA 0
NCT03363893 Phase Ib/II ICEC0942 Fulvestrant + ICEC0942 Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies Active, not recruiting USA 1
NCT03365791 Phase II LAG525 Spartalizumab PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies Completed USA 0
NCT03366103 Phase Ib/II Navitoclax + Vistusertib Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors Active, not recruiting USA 0
NCT03371979 Phase Ib/II Pegzilarginase + Pembrolizumab Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer Completed USA 1
NCT03382561 Phase II Cisplatin + Etoposide + Nivolumab Carboplatin + Etoposide + Nivolumab Cisplatin + Etoposide Carboplatin + Etoposide Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Lung Cancer Active, not recruiting USA 0
NCT03402880 Phase II Epacadostat + Pembrolizumab ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer Withdrawn USA 0
NCT03406715 Phase II Ad.p53-DC vaccine + Ipilimumab + Nivolumab Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC) Active, not recruiting USA 0
NCT03460977 Phase I PF-06821497 PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma Recruiting USA 2
NCT03467360 Phase I Atezolizumab Inhibition of CArbonic Anhydrase in Combination With Platinum and Etoposide-based Radiochemotherapy in Patients With Localized Small Cell Lung Cancer (ICAR) Recruiting 1
NCT03509012 Phase I Carboplatin + Cisplatin + Durvalumab + Etoposide + Tremelimumab Carboplatin + Cisplatin + Durvalumab + Pemetrexed Disodium Cisplatin + Durvalumab + Etoposide Cisplatin + Durvalumab Carboplatin + Durvalumab + Paclitaxel Carboplatin + Cisplatin + Durvalumab + Etoposide Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (CLOVER) Active, not recruiting USA 4
NCT03517488 Phase I XmAb20717 A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) Recruiting USA 0
NCT03532880 Phase I Olaparib A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer Recruiting USA 0
NCT03538028 Phase I INCAGN02385 A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies Completed USA 0
NCT03554473 Phase Ib/II M7824 + Topotecan M7824 + Temozolomide M7824 M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers Suspended USA 0
NCT03568539 Phase Ib/II Sintilimab IBI308 in Subjects With Advanced/Metastatic Solid Malignancies Completed USA 0
NCT03575793 Phase Ib/II Ipilimumab + Nivolumab + Plinabulin Ipilimumab + Nivolumab A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer Recruiting USA 0
NCT03595059 Phase I Docetaxel + Mirzotamab clezutoclax Mirzotamab clezutoclax + Paclitaxel Mirzotamab clezutoclax A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors Recruiting USA | CAN 5
NCT03639194 Phase I ABBV-011 + ABBV-181 ABBV-011 A Study of SC-011 Alone and in Combination With ABBV-181 in Subjects With Relapsed or Refractory Small Cell Lung Cancer Recruiting USA 2
NCT03662074 Phase II Gemcitabine + Nivolumab Second Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer Active, not recruiting USA 0
NCT03670056 Phase II Ipilimumab + Nivolumab A Pilot Study of Combination Immunotherapy With Ipilimumab and Nivolumab in Patients With Recurrent Extensive Stage Small Cell Lung Cancer (SCLC) Who Have Previously Received Platinum-based Chemotherapy Active, not recruiting USA 0
NCT03672773 Phase II Talazoparib + Temozolomide Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer Recruiting USA 0
NCT03694249 Phase II Ifetroban sodium Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence Recruiting USA 0
NCT03703297 Phase III Durvalumab Durvalumab + Tremelimumab Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Stage I-III Limited Disease Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC) Active, not recruiting USA | CAN 18
NCT03708328 Phase I RO7121661 A Dose Escalation and Expansion Study of RO7121661, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors Active, not recruiting USA 5
NCT03728361 Phase II Nivolumab + Temozolomide Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer Active, not recruiting USA 0
NCT03752398 Phase I XmAb23104 A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3) Recruiting USA 0
NCT03761914 Phase Ib/II Galinpepimut-S Galinpepimut-S + Pembrolizumab Pembrolizumab Sargramostim Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers Recruiting USA 0
NCT03811002 Phase II Atezolizumab + Carboplatin + Etoposide Atezolizumab + Cisplatin + Etoposide Cisplatin + Etoposide Carboplatin + Etoposide Chemoradiation With or Without Atezolizumab in Treating Patients With Limited Stage Small Cell Lung Cancer Recruiting USA 1
NCT03811652 Phase I MEDI7247 A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors Completed USA | CAN 0
NCT03816345 Phase I Nivolumab Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer Recruiting USA | CAN 0
NCT03830918 Phase Ib/II Niraparib + Temozolomide Niraparib and Temozolomide in Treating Patients With Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy Recruiting USA 0
NCT03849469 Phase I Pembrolizumab + XmAb22841 XmAb22841 A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4) Recruiting USA 0
NCT03850067 Phase Ib/II Carboplatin + CC-90011 + Etoposide CC-90011 + Cisplatin + Etoposide Nivolumab A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer Recruiting 3
NCT03879798 Phase Ib/II DS-3201b + Irinotecan DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer Recruiting USA 0
NCT03896503 Phase II Topotecan Berzosertib + Topotecan Topotecan With or Without M6620 in Treating Patients With Relapsed Small Cell Lung Cancer or Extrapulmonary Small Cell Cancer Recruiting USA 0
NCT03898791 Phase Ib/II LY3295668 A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer Completed USA 7
NCT03913455 Phase II Carboplatin + Guadecitabine Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer Active, not recruiting USA 0
NCT03923270 Phase I Durvalumab + Tremelimumab Durvalumab Durvalumab + Olaparib Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer Recruiting USA 0
NCT03936959 Phase I LY3434172 A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer Completed USA 4
NCT03958045 Phase II Nivolumab + Rucaparib Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma Recruiting USA 0
NCT03963414 Phase I Carboplatin + Durvalumab + Etoposide + Tremelimumab Carboplatin + Durvalumab + Etoposide A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC Recruiting USA 0
NCT03964727 Phase II Sacituzumab govitecan-hziy A Study of Sacituzumab Govitecan in Metastatic Solid Tumors (Tropics-03) Recruiting USA 0
NCT03977467 Phase II Atezolizumab + Carboplatin Atezolizumab + Cisplatin Atezolizumab Atezolizumab + Bevacizumab + Carboplatin Atezolizumab + Bevacizumab + Cisplatin Atezolizumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor Recruiting USA 0
NCT04010357 Phase II Abemaciclib Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC Recruiting USA 0
NCT04022876 Phase I ALRN-6924 + Carboplatin + Pemetrexed Disodium ALRN-6924 + Topotecan Carboplatin + Pemetrexed Disodium A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection) Recruiting USA 4
NCT04032704 Phase II Ladiratuzumab vedotin A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors Recruiting USA 5
NCT04047862 Phase I BGBA1217 + Tislelizumab BGBA1217 + Cisplatin + Pemetrexed Disodium + Tislelizumab BGBA1217 + Carboplatin + Pemetrexed Disodium + Tislelizumab BGBA1217 + Carboplatin + Paclitaxel + Tislelizumab BGBA1217 + Carboplatin + Nab-paclitaxel + Tislelizumab BGBA1217 + Cisplatin + Etoposide + Tislelizumab BGBA1217 + Carboplatin + Etoposide + Tislelizumab Study of BGB-A1217 in Combination With Tislelizumab in Advanced Solid Tumors Recruiting USA 5
NCT04101357 Phase Ib/II BNT411 Atezolizumab + BNT411 + Carboplatin + Etoposide Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411 Recruiting USA 3
NCT04122625 Phase Ib/II Debio 1143 + Nivolumab Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143 (SMARTPLUS-106) Active, not recruiting USA 2
NCT04134312 Phase I MVA-BN-Brachyury A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer Completed USA 0
NCT04165330 Phase Ib/II Anlotinib + Nivolumab Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors Recruiting USA 0
NCT04170946 Phase I Talazoparib Talazoparib and Thoracic RT for ES-SCLC Recruiting CAN 0
NCT04173325 Phase I Nivolumab Irinotecan + Nivolumab Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer Recruiting USA 0
NCT04209595 Phase Ib/II PLX038 + Rucaparib PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers Suspended USA 0
NCT04210037 Phase Ib/II APG-1252 + Paclitaxel Study of Combination APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer Active, not recruiting USA 1
NCT04221529 Phase II Atezolizumab Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide (SPACE) Recruiting 2
NCT04246671 Phase Ib/II TAEK-VAC-HerBy TAEK-VAC-HerBy + unspecified ERBB2 antibody + unspecified immune checkpoint inhibitor Pertuzumab + TAEK-VAC-HerBy + Trastuzumab Ado-trastuzumab emtansine + TAEK-VAC-HerBy TAEK-VAC-HerBy + Trastuzumab Intravenous TAEK-VAC-HerBy Vaccine Alone and in Combination Treatment in HER2 Cancer Patients Recruiting USA 0
NCT04253145 Phase I Atezolizumab + Lurbinectedin Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer. Recruiting 1
NCT04256421 Phase III Atezolizumab + Carboplatin + Etoposide + MTIG7192A Atezolizumab + Carboplatin + Etoposide A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (SKYSCRAPER-02) Active, not recruiting USA 22
NCT04332653 Phase Ib/II NT-I7 + Pembrolizumab NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (KEYNOTE A60) Recruiting USA 0
NCT04334941 Phase II Atezolizumab + Talazoparib Atezolizumab Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker Recruiting USA 0
NCT04350463 Phase II CC-90011 + Nivolumab A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers Recruiting USA 5
NCT04358237 Phase Ib/II Lurbinectedin + Pembrolizumab Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer. (LUPER) Recruiting 1
NCT04373369 Phase II Atezolizumab + Vorolanib Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer Recruiting USA 0
NCT04397003 Phase II Carboplatin + Durvalumab + Etoposide Durvalumab + Tremelimumab Durvalumab + Personalized cancer vaccine + Tremelimumab Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) and Tremelimumab in Extensive Stage Small Cell Lung Cancer Not yet recruiting USA 0
NCT04402788 Phase II Atezolizumab Atezolizumab + Radiotherapy Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial Recruiting USA 0
NCT04422210 Phase I Atezolizumab + Venetoclax Atezolizumab + Carboplatin + Etoposide + Venetoclax A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC). Terminated USA 3
NCT04423029 Phase Ib/II DF6002 + Pembrolizumab DF6002 Dose Escalation of DF6002 in Patients With Advanced Solid Tumors, and Expansion in Selected Indications Recruiting USA 0
NCT04429087 Phase I BI 764532 A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for Delta-Like Ligand 3 (DLL3). Recruiting USA 3
NCT04462276 Phase II Atezolizumab Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease (TREASURE) Recruiting 2
NCT04471727 Phase Ib/II HPN328 Study in Patients With Advanced Cancers Associated With Expression of DLL3 Who Have Failed Standard Available Therapy Recruiting USA 0
NCT04487756 Phase Ib/II Atezolizumab + Carboplatin + Etoposide Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung Cancer (VENEZO-LUNG) Recruiting 1
NCT04491942 Phase I BAY1895344 + Cisplatin BAY1895344 + Cisplatin + Gemcitabine Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer Recruiting USA 0
NCT04504669 Phase I AZD8701 + Durvalumab AZD8701 First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours Recruiting USA | CAN 2
NCT04514484 Phase I Cabozantinib + Nivolumab Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Recruiting USA 0
NCT04514497 Phase I BAY1895344 + Irinotecan BAY1895344 + Topotecan Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer Recruiting USA 0
NCT04521413 Phase Ib/II CFI-402411 + Pembrolizumab CFI-402411 Safety and Efficacy Study Of CFI-402411 in Subjects With Advanced Solid Malignancies Recruiting USA | CAN 1
NCT04538378 Phase II Durvalumab + Olaparib Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors Recruiting USA 0
NCT04543916 Phase Ib/II Irinotecan + Venetoclax Venetoclax and Irinotecan in Relapsed/Refractory SCLC Withdrawn 0
NCT04553133 Phase II PF-07104091 Letrozole + Palbociclib + PF-07104091 Palbociclib + PF-07104091 PF-07104091 as a Single Agent and in Combination Therapy Recruiting USA 0
NCT04560972 Phase I Atezolizumab + Carboplatin + Etoposide + LB-100 Atezolizumab + LB-100 LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer Recruiting USA 0
NCT04579757 Phase Ib/II Surufatinib + Tislelizumab Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors Recruiting USA 0
NCT04590781 Phase Ib/II Pembrolizumab + XmAb18087 XmAb18087 Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer Recruiting USA 0
NCT04602533 Phase II Cisplatin + Etoposide Durvalumab Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN) Recruiting 1
NCT04607954 Phase II Durvalumab + Topotecan Durvalumab and Topotecan for the Treatment of Relapsed or Refractory Small Cell Lung Cancer Recruiting USA 0
NCT04610658 Phase Ib/II Ipilimumab + Lurbinectedin + Nivolumab Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC Recruiting USA 0
NCT04610684 Phase II Atezolizumab Atezolizumab + Carboplatin + Etoposide Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases Recruiting USA 0
NCT04624204 Phase III Pembrolizumab Cisplatin + Etoposide Cisplatin + Etoposide + Pembrolizumab Carboplatin + Etoposide Olaparib + Pembrolizumab Carboplatin + Etoposide + Pembrolizumab Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013) Recruiting USA | CAN 17
NCT04631029 Phase I Atezolizumab + Carboplatin + Entinostat + Etoposide Atezolizumab + Entinostat Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread Suspended USA 0
NCT04641871 Phase I Sym021 + Sym023 Sym021 + Sym022 Sym021 in Combination With Either Sym022 or Sym023 in Patients With Advanced Solid Tumor Malignancies Active, not recruiting USA | CAN 2
NCT04696575 Phase II Atezolizumab + Carboplatin + Etoposide + Lamivudine Atezolizumab + Lamivudine Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer Recruiting USA 0
NCT04699838 Phase II Carboplatin + Ceralasertib + Durvalumab + Etoposide Ceralasertib + Cisplatin + Durvalumab + Etoposide Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer Recruiting USA 0
NCT04701307 Phase II Dostarlimab-gxly + Niraparib Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas Recruiting USA 0
NCT04702880 Phase II BMS-986012 + Carboplatin + Etoposide + Nivolumab Carboplatin + Etoposide + Nivolumab A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer Recruiting USA | CAN 9
NCT04728230 Phase Ib/II Carboplatin + Durvalumab + Etoposide + Olaparib Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial Recruiting USA 0
NCT04730999 Phase II Atezolizumab + Bevacizumab + Carboplatin + Etoposide Efficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung Cancer (CeLEBrATE) Recruiting 1
NCT04745689 Phase II AZD2811 + Durvalumab Cisplatin + Durvalumab + Etoposide Carboplatin + Durvalumab + Etoposide Study of AZD2811 + Durvalumab in ES-SCLC (TAZMAN) Recruiting USA | CAN 6
NCT04768296 Phase II Berzosertib + Topotecan Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250) Recruiting USA 6
NCT04774380 Phase III Cisplatin + Durvalumab + Etoposide Carboplatin + Durvalumab + Etoposide Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer (LUMINANCE) Not yet recruiting CAN 5
NCT04802174 Phase Ib/II Berzosertib + Lurbinectedin A Phase I/II Trial of Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High Grade Neuroendocrine Cancers Recruiting USA 0
NCT04826341 Phase Ib/II Berzosertib + Sacituzumab govitecan-hziy A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors Recruiting USA 0
NCT04827576 Phase II Docetaxel + Hu5F9-G4 Study of Magrolimab in Participants With Solid Tumors Recruiting USA 0
NCT04834778 Phase I HC-5404-FU A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD) Recruiting USA 0
NCT04836195 Phase I PCLX-001 Phase I Trial of PCLX-001 in B-cell Non-Hodgkin Lymphoma and Advanced Solid Malignancies Recruiting CAN 0
NCT04837677 Phase I PRT1419 A Study of PRT1419 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT04870112 Phase Ib/II Carboplatin + Cisplatin + Durvalumab + Etoposide Durvalumab A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer (SCope-D1) Recruiting USA 3
NCT04885998 Phase I AMG 404 + AMG 757 AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC) Recruiting USA 1
NCT04902040 Phase Ib/II Atezolizumab + Avelumab + Durvalumab + Nivolumab + Pembrolizumab + Plinabulin Atezolizumab + Avelumab + Durvalumab + Nivolumab + Pembrolizumab Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies Recruiting USA 0
NCT04919382 Phase II Atezolizumab + Temozolomide Temozolomide and Atezolizumab as Second Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer Not yet recruiting USA 0
NCT04923776 Phase II Atezolizumab + Carboplatin + Etoposide Liver Directed RT + Chemo-immunotherapy for ES-SCLC Not yet recruiting USA 0
NCT04924101 Phase II Cisplatin + Etoposide + Lenvatinib + Pembrolizumab Carboplatin + Etoposide + MK-5890 + Pembrolizumab Carboplatin + Etoposide + Lenvatinib + Pembrolizumab Carboplatin + Etoposide + MK-4830 + Pembrolizumab Cisplatin + Etoposide + MK-5890 + Pembrolizumab Cisplatin + Etoposide + MK-4830 + Pembrolizumab Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99) Recruiting USA 8
NCT04938817 Phase Ib/II Lenvatinib + MK-1308A MK-1308A MK-4280A MK-1308A + MK-4830 Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Investigational Agents for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98) Recruiting USA 8
NCT04951115 Phase II Cisplatin + Durvalumab + Etoposide Carboplatin + Durvalumab + Etoposide A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer Recruiting USA 0
NCT04952597 Phase II Tislelizumab BGBA1217 + Tislelizumab Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer Recruiting USA 2
NCT05006794 Phase I GS-9716 + Sacituzumab govitecan-hziy GS-9716 Docetaxel + GS-9716 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies Recruiting USA 0
NCT05091567 Phase III Atezolizumab + Carboplatin + Etoposide Atezolizumab + Carboplatin + Etoposide + Lurbinectedin A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer (IMforte) Not yet recruiting USA 9